These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24582759)

  • 61. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.
    Abbas M; Lalive PH; Chofflon M; Simon HU; Chizzolini C; Ribi C
    Neurology; 2011 Oct; 77(16):1561-4. PubMed ID: 21975205
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Benign multiple sclerosis is characterized by a stable neuroimmunologic network.
    Haase CG; Faustmann PM
    Neuroimmunomodulation; 2004; 11(4):273-7. PubMed ID: 15249735
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are antioxidant parameters in serum altered in patients with relapsing-remitting multiple sclerosis treated with II-line immunomodulatory therapy?
    Adamczyk B; Koziarska D; Kasperczyk S; Adamczyk-Sowa M
    Free Radic Res; 2018 Oct; 52(10):1083-1093. PubMed ID: 30326767
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical evaluation of natalizumab for formulary consideration.
    Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
    Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.
    Papeix C; Depaz R; Tourbah A; Stankoff B; Lubetzki C
    Mult Scler; 2011 Dec; 17(12):1520-2. PubMed ID: 21669937
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Severe anemia in a patient with multiple sclerosis treated with natalizumab.
    Simone AM; Ferraro D; Vitetta F; Marasca R; Bonacorsi G; Pinelli G; Federzoni L; Nichelli PF; Sola P
    Neurology; 2014 Jul; 83(4):374-5. PubMed ID: 24944259
    [No Abstract]   [Full Text] [Related]  

  • 69. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.
    Sangalli F; Moiola L; Bucello S; Annovazzi P; Rizzo A; Radaelli M; Vitello G; Grimaldi LM; Ghezzi A; Martinelli V; Comi G
    Neurol Sci; 2011 Jan; 31 Suppl 3():299-302. PubMed ID: 20544247
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.
    Outteryck O; Ongagna JC; Brochet B; Rumbach L; Lebrun-Frenay C; Debouverie M; Zéphir H; Ouallet JC; Berger E; Cohen M; Pittion S; Laplaud D; Wiertlewski S; Cabre P; Pelletier J; Rico A; Defer G; Derache N; Camu W; Thouvenot E; Moreau T; Fromont A; Tourbah A; Labauge P; Castelnovo G; Clavelou P; Casez O; Hautecoeur P; Papeix C; Lubetzki C; Fontaine B; Couturier N; Bohossian N; Clanet M; Vermersch P; de Sèze J; Brassat D; ;
    Eur J Neurol; 2014; 21(1):40-8. PubMed ID: 23895407
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.
    Ramos-Cejudo J; Oreja-Guevara C; Stark Aroeira L; Rodriguez de Antonio L; Chamorro B; Diez-Tejedor E
    J Clin Immunol; 2011 Aug; 31(4):623-31. PubMed ID: 21491095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Disease activity return after natalizumab cessation in multiple sclerosis.
    Rasenack M; Derfuss T
    Expert Rev Neurother; 2016 May; 16(5):587-94. PubMed ID: 26988737
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Neurol Sci; 2011 Jan; 31 Suppl 3():317-20. PubMed ID: 20535514
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
    J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
    Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report.
    Văcăraş V; Major ZZ; Buzoianu AD
    Neurol Neurochir Pol; 2017; 51(3):221-226. PubMed ID: 28392137
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Natalizumab in clinical practice: managing the risks, enjoying the benefits.
    Aktas O
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1181. PubMed ID: 24659794
    [No Abstract]   [Full Text] [Related]  

  • 78. Severe haematological complications during treatment with natalizumab.
    Midaglia L; Rodriguez Ruiz M; Muñoz-García D
    Mult Scler; 2012 Nov; 18(11):1644-6. PubMed ID: 22438058
    [TBL] [Abstract][Full Text] [Related]  

  • 79. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.
    Burman J; Fransson M; Tötterman TH; Fagius J; Mangsbo SM; Loskog AS
    Immunology; 2013 Oct; 140(2):211-9. PubMed ID: 23721329
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
    de Andrés C; Teijeiro R; Alonso B; Sánchez-Madrid F; Martínez ML; Guzmán de Villoria J; Fernández-Cruz E; Sánchez-Ramón S
    PLoS One; 2012; 7(4):e34103. PubMed ID: 22496780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.